Soy may protect against breast cancer in Asian women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 4
Volume 18
Issue 4

Asian-American women who consumed large amounts of soy as children have a 58% reduced risk of breast cancer, according to a study conducted at National Cancer Institute’s Clinical Genetics Branch.

Asian-American women who consumed large amounts of soy as children have a 58% reduced risk of breast cancer, according to a study conducted at National Cancer Institute’s Clinical Genetics Branch.

Larissa Korde, MD, and colleagues interviewed 597 women with breast cancer and 966 health women of Chinese, Japanese, and Filipino descent living in San Francisco, Oakland, Los Angeles, or Hawaii (Cancer Epidemiol Biomarkers Prev online, March 24, 2009).

The researchers found that high intake of soy in childhood was associated with a 58% reduction in breast cancer. A high intake during adolescent and adult years was associated with a 20 % to 25% reduction. “Since the effects of childhood soy intake could not be explained by measures other than Asian lifestyle during childhood or adult life, early soy intake might itself be protective,” Dr. Korde said.

Commenting on the research, Regina Ziegler, PhD, said it would be premature to recommend changes in childhood diet. Dr. Ziegler is a senior investigator in the NCI Division of Cancer Epidemiology and Genetics.

 

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content